De Novo device
RefleXion Medical Radiotherapy System, Reflexion X2
Reflexion Medical, Inc. · Fludeoxyglucose F18-Guided Radiation Therapy System (QVA, Class II) · First FDA decision Feb 1, 2023, newest Dec 18, 2025Cancer radiation therapy
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
160
Naming "Medical Radiotherapy"
MAUDE reports
35
Brand "Medical Radiotherapy", since 2015
PubMed studies
21
Mentioning "Medical Radiotherapy"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K252071 · Decided Dec 18, 2025 · 170 days after receipt
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA) · Radiology & Imaging
- RefleXion Medical Radiotherapy System (RMRS)New device typeBreakthroughDe Novo
DEN220014 · Decided Feb 1, 2023 · 343 days after receipt
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hyperbaric Oxygen Therapy for Chronic Radiation Induced Proctitis and EnteritisNational analysisReview closedCAG-00060R2Updated Nov 18, 2026
- Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)Local determinationIn effectL35076Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40168Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40179CGS Administrators, LLCUpdated Apr 17, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40193WPS Insurance CorporationUpdated Mar 12, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40189Palmetto GBAUpdated Mar 11, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40176Noridian Healthcare Solutions, LLCUpdated Mar 10, 2026
- Intraoperative Radiation TherapyLocal determinationIn effectL37779Palmetto GBAUpdated Jul 23, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "Medical Radiotherapy", any status and sponsor, newest update first.
- Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After RadiotherapyPivotal-lookingCompleted
Centre Leon BerardAcademic, hospital or other
NCT05944913 · 173 participants · Start Aug 3, 2023 · Primary completion Oct 7, 2026
Device: Prevena · For: Soft Tissue Sarcoma
Sites: Nantes, France; Lyon, France; Angers, France · 14 sites in all
- Automated Radiation Target Contouring and Treatment Planning Via RATA: A Multi-Center RCTNot yet recruiting
zhaoxiaohuiAcademic, hospital or other
NCT07922902 · 62 participants (planned) · Start Nov 9, 2026 · Primary completion Feb 1, 2029
Device: RATA (Radiotherapy Treatment Multi-Agent Assistant) System · For: Cancer; Malignant Neoplasms; Radiotherapy
Sites: Guangzhou, China
- Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)Active, not recruiting
Ion Beam ApplicationsNot on our public-company list
NCT07137195 · 47 participants · Start Apr 29, 2025 · Primary completion Aug 31, 2026
Device: Proton Beam Therapy (PBT) · For: Solid Tumor, Adult
Sites: Zhuozhou, China
- Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)Active, not recruiting
Ion Beam ApplicationsNot on our public-company list
NCT07152353 · 47 participants · Start Aug 19, 2025 · Primary completion Aug 31, 2026
Device: Proton Beam Therapy (PBT) · For: Solid Tumor, Adult
Sites: Chengdu, China
- Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)Active, not recruiting
Ion Beam ApplicationsNot on our public-company list
NCT07153094 · 47 participants · Start Aug 4, 2025 · Primary completion Aug 31, 2026
Device: Proton Beam Therapy (PBT) · For: Solid Tumor, Adult
Sites: Shenzhen, China
- Positioning in RT - Supine vs. UprightNot yet recruiting
University Health Network, TorontoAcademic, hospital or other
NCT07765069 · 105 participants (planned) · Start Dec 1, 2026 · Primary completion Nov 30, 2027
Device: Upright positioning chair · For: Cancer
Sites: Toronto, Canada
Mayo ClinicAcademic, hospital or other
NCT05547347 · 15 participants (planned) · Start Mar 21, 2023 · Primary completion Nov 30, 2027
Device: Twinkle marker · For: Anatomic Stage III Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Resectable Breast Carcinoma
Sites: Rochester, Minnesota
Apreo Health, Inc.Not on our public-company list
NCT07896902 · 15 participants (planned) · Start Oct 2026 · Primary completion Apr 2028
Device: Apreo BREATHE Airway Scaffold · For: Air Trapping; Emphysema; Hyperinflation
Sites: Birmingham, Alabama; Kansas City, Kansas
- Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC)Not yet recruiting
Torskal SASAcademic, hospital or other
NCT07891949 · 78 participants (planned) · Start Oct 2026 · Primary completion Oct 2026
Device: TSK-001. Injectable solution of glucose-functionalised plasmonic gold nanoparticles (0.3 mg in 1 mL water for injection) for intratumoural administration.; 808 nm near-infrared (NIR) diode laser (Hyper Diode 808) · For: Nodular BCC
Sites: Wellington, New Zealand
Washington University School of MedicineAcademic, hospital or other
NCT07221825 · 38 participants (planned) · Start Nov 1, 2026 · Primary completion Apr 30, 2028
Device: Low-count quantitative single-photon emission computed tomography imaging · For: Prostate Cancer; Cancer of the Prostate
Sites: St Louis, Missouri
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Medical Radiotherapy", and for the whole product code for context.
This brand
35 reports: 12 malfunction, 23 injury, 0 death
Whole product code QVA
42 reports: 18 malfunction, 24 injury, 0 death
Newest reports for this brand
3011716550-2026-00012 · Received Apr 3, 2026 · Event dated Jan 4, 2024
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA)
Device problem as coded: Program or Algorithm Execution Problem
Patient problem as coded: Insufficient Information
3011716550-2026-00028 · Received Apr 3, 2026 · Event dated Apr 15, 2025
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA)
Device problem as coded: Program or Algorithm Execution Problem
Patient problem as coded: Insufficient Information
3011716550-2026-00029 · Received Apr 3, 2026 · Event dated Mar 6, 2025
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA)
Device problem as coded: Program or Algorithm Execution Problem
Patient problem as coded: Insufficient Information
3011716550-2026-00030 · Received Apr 3, 2026 · Event dated Oct 23, 2024
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA)
Device problem as coded: Program or Algorithm Execution Problem
Patient problem as coded: Insufficient Information
3011716550-2026-00031 · Received Apr 3, 2026 · Event dated Jan 15, 2026
Device type: Fludeoxyglucose F18-Guided Radiation Therapy System (QVA)
Device problem as coded: Program or Algorithm Execution Problem
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Medical Radiotherapy"[tiab]. The summary above synthesizes these.
- Trapping and acceleration of relativistic electrons by uniform radially polarized Bessel-Gauss beams.
Ye H, Cao L, Wang X, et al. · Opt Express · 2025
- Advances on inorganic scintillator-based optic fiber dosimeters.
Ding L, Wu Q, Wang Q, et al. · EJNMMI Phys · 2020Review
- Characteristics of acromegaly in Korea with a literature review.
Hong JW, Ku CR, Kim SH, et al. · Endocrinol Metab (Seoul) · 2013Review
- Depleted and natural uranium: chemistry and toxicological effects.
Craft E, Abu-Qare A, Flaherty M, et al. · J Toxicol Environ Health B Crit Rev · 2004Review
- Non urothelial bladder cancers: a case series.
Ravi K, Kumar T, Bakshi H, et al. · Indian J Surg Oncol · 2013
- Impact of Structured Nurse Leader Rounds on Satisfaction With Nursing Care Among Patients With Cancer.
Ayaad O, Alloubani A, Al-Rafaay M, et al. · J Nurs Scholarsh · 2019
- Vertebral augmentation for compression fractures caused by malignant disease.
Rastogi R, Patel T, Swarm RA · J Natl Compr Canc Netw · 2010Case Reports
- Shielding performance of polyaniline-cobalt ferrite composite materials against hazardous gamma-rays and fast neutrons.
Thakur S, Kaur P · Appl Radiat Isot · 2026
- A Prospective First-In-Human Pilot Study 18F-DCFPyL Prostate-Specific Membrane Antigen Imaging on the RefleXion X1 Positron Emission Tomography-Computed Tomograpghy Subsystem in Patients with Prostate Cancer.
Liu B, Dandapani S, Li Y, et al. · Adv Radiat Oncol · 2025
- Combined medical radiotherapy: clinical conference.
NICKSON JJ, GLICKSMAN AS · CA Cancer J Clin · 1958
- Evolving societal risks and necessary precautions in the age of nuclear power and therapeutic radiation: an American perspective.
Pham MH, Yu C, Rusch M, et al. · World Neurosurg · 2014
- [Application Status and Development Trends of Medical Proton and Heavy Ion Accelerators].
Yang X, Chen H, Chen J, et al. · Zhongguo Yi Liao Qi Xie Za Zhi · 2019Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.